<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02273843</url>
  </required_header>
  <id_info>
    <org_study_id>MS 306</org_study_id>
    <nct_id>NCT02273843</nct_id>
  </id_info>
  <brief_title>A Trial on Different Dosages of Vitamin D in Preterm Infants With Late-onset Sepsis</brief_title>
  <official_title>Effect of Different Dosages Oral Vitamin D on Serum Interleukin-6 in Preterm Infants With Late-onset Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University Children Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University Children Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial (RCT) to evaluate the influence of different doses of
      vitamin D3 (800 IU/d versus 400 IU/d), on serum levels of interleukin (IL)-6, TNF-alpha and
      C- reactive (CRP) in premature infants with clinical evidence of late-onset sepsis and to
      assess its influence on clinical outcomes of these infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D has an important role in the regulation of both the innate and adaptive immune
      systems. There are very few studies of such roles in the neonatal population. It is
      potentially an attractive therapeutic agent for sepsis given its low cost and low risk of
      toxicity and side effects. There is no consensus regarding to the dose of vitamin D
      supplementation required for preterm infants given the paucity of evidence. AAP and ESPGHAN
      have recommended different dosages of vitamin D ranging from 400 IU to 1000 IU per day. The
      influence of different doses of vitamin D on immunological status and clinical outcomes of
      preterm infants with late-onset sepsis has not been evaluated before. This RCT will evaluate
      the influence of different doses of vitamin D3 (800 IU/d versus 400 IU/d), on serum levels of
      interleukin (IL)-6, TNF-alpha and C- reactive (CRP) in premature infants with clinical
      evidence of late-onset sepsis we will also evaluate their safety and influence on clinical
      outcomes of these infants
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum interleukin-6</measure>
    <time_frame>At trial entry and 7 days after daily vitamin D supplementation therapy</time_frame>
    <description>Serum levels of interleukin-6 (IL-6) will be evaluated at enrollment and 7 days after daily vitamin D supplementation therapy. IL-6 concentrations will be determined by Endogenous Interleukin-ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum tumor necrosis-alpha</measure>
    <time_frame>At trial entry and 7 days after daily vitamin D supplementation therapy</time_frame>
    <description>Serum levels of tumor necrosis-alpha (TNF-alpha) will be evaluated at enrollment and 7 days after daily vitamin D supplementation therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum C-reactive protein (CRP)</measure>
    <time_frame>At trial entery and 7 days after daily vitamin D supplementation therapy</time_frame>
    <description>Serum CRP will be evaluated at enrollment and 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum 25(OH)D levels</measure>
    <time_frame>at trial entry, 7 days after daily vitamin D supplementation therapy and at 40 weeks postmenstrual age</time_frame>
    <description>Serum 25(OH)D levels will be measured by ELISA at trial entry, at day 7 and at 40 weeks postmenstrual age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum calcium, phosphorus and urinary calcium</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, serum calcium, phosphorus and urinary calcium well be assessed every week for an expected average of 5 weeks</time_frame>
    <description>Participants will be followed for the duration of hospital stay, serum calcium, phosphorus and urinary calcium well be assessed every week for an expected average of 5 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal ultrasonography</measure>
    <time_frame>40 weeks postmenstrual age</time_frame>
    <description>Abdominal ultrasonography to detect any nephrocalcinosis will be done at 40 weeks postmenstrual age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Baseline</time_frame>
    <description>In-hospital mortality during NICU admission for an expected average of 5 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal morbidities</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, for an expected average of 4 weeks</time_frame>
    <description>Participants will be followed for the duration of hospital stay, for an expected average of 5 weeks and the incidence of neonatal morbidities e.g. NEC, retinopathy of prematurity, disseminated intravascular coagulopathy and renal dysfunction will be assessed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Prematurity</condition>
  <condition>Late-onset Sepsis</condition>
  <arm_group>
    <arm_group_label>High-dose vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 800 IU from the time of diagnosis of sepsis until discharge from the NICU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional-dose vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 400 IU from the time of diagnosis of sepsis until discharge from the NICU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose vitamin D 3</intervention_name>
    <description>Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 800 IU from the time of diagnosis of sepsis until discharge from the NICU</description>
    <arm_group_label>High-dose vitamin D</arm_group_label>
    <other_name>High-dose cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional-Dose Vitamin D 3</intervention_name>
    <description>Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 400 IU from the time of diagnosis of sepsis until discharge from the NICU</description>
    <arm_group_label>Conventional-dose vitamin D</arm_group_label>
    <other_name>Conventional-dose cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preterm Infants (28-37 wk gestational age)

          -  Late-onset sepsis defined as clinical signs suggestive of infection after 72 h of
             birth. Clinical sepsis will be defined as the presence of three or more of the
             following categories of clinical signs:

               1. Temperature instability (hypothermia, hyperthermia);

               2. Respiratory (grunting, intercoastal retraction, apnea, tachypnea, cyanosis);

               3. Neurologic (hypotonia, lethargy, seizures);

               4. Gastrointestinal (feeding intolerance, abdominal distension).

        Exclusion Criteria:

          -  Major congenital anomalies.

          -  Chromosomal anomalies.

          -  Known inborn error(s) of metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Neonatal Intensive Care Unit, Mansoura University Children Hospital</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlia</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Moromizato T, Litonjua AA, Braun AB, Gibbons FK, Giovannucci E, Christopher KB. Association of low serum 25-hydroxyvitamin D levels and sepsis in the critically ill. Crit Care Med. 2014 Jan;42(1):97-107. doi: 10.1097/CCM.0b013e31829eb7af.</citation>
    <PMID>23982028</PMID>
  </reference>
  <reference>
    <citation>Hewison M. Vitamin D and the immune system: new perspectives on an old theme. Endocrinol Metab Clin North Am. 2010 Jun;39(2):365-79, table of contents. doi: 10.1016/j.ecl.2010.02.010. Review.</citation>
    <PMID>20511058</PMID>
  </reference>
  <reference>
    <citation>Kim SY. The pleiomorphic actions of vitamin D and its importance for children. Ann Pediatr Endocrinol Metab. 2013 Jun;18(2):45-54. doi: 10.6065/apem.2013.18.2.45. Epub 2013 Jun 30. Review.</citation>
    <PMID>24904851</PMID>
  </reference>
  <reference>
    <citation>Agostoni C, Buonocore G, Carnielli VP, De Curtis M, Darmaun D, Decsi T, Domell√∂f M, Embleton ND, Fusch C, Genzel-Boroviczeny O, Goulet O, Kalhan SC, Kolacek S, Koletzko B, Lapillonne A, Mihatsch W, Moreno L, Neu J, Poindexter B, Puntis J, Putet G, Rigo J, Riskin A, Salle B, Sauer P, Shamir R, Szajewska H, Thureen P, Turck D, van Goudoever JB, Ziegler EE; ESPGHAN Committee on Nutrition. Enteral nutrient supply for preterm infants: commentary from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition. J Pediatr Gastroenterol Nutr. 2010 Jan;50(1):85-91. doi: 10.1097/MPG.0b013e3181adaee0.</citation>
    <PMID>19881390</PMID>
  </reference>
  <reference>
    <citation>Abrams SA; Committee on Nutrition. Calcium and vitamin d requirements of enterally fed preterm infants. Pediatrics. 2013 May;131(5):e1676-83. doi: 10.1542/peds.2013-0420. Epub 2013 Apr 29. Review.</citation>
    <PMID>23629620</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <last_update_submitted>September 29, 2015</last_update_submitted>
  <last_update_submitted_qc>September 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University Children Hospital</investigator_affiliation>
    <investigator_full_name>Hesham Abdel-Hady</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Preterm</keyword>
  <keyword>late-onset sepsis</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Dose</keyword>
  <keyword>Interleukin-6</keyword>
  <keyword>Tumor necrosis factor-alpha</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

